Currently out of the existing stock ratings of David Dai, 39 are a BUY (84.78%), 7 are a HOLD (15.22%).

David Dai

Work Performance Price Targets & Ratings Chart

Analyst David Dai, currently employed at UBS, carries an average stock price target met ratio of 30.76% that have a potential upside of 11.32% achieved within 65 days. Previously, David Dai worked at BERNSTEIN.

David Dai’s has documented 96 price targets and ratings displayed on 19 stocks. The coverage is on Healthcare, Technology sectors.

Most recent stock forecast was given on NRIX, Nurix Therapeutics at 22-Jul-2026.

Wall Street Analyst David Dai

Analyst best performing recommendations are on ASML (ASML HOLDING NV ADR).
The best stock recommendation documented was for ASML (ASML HOLDING NV ADR) at 10/9/2025. The price target of $935 was fulfilled within 1 day with a profit of $42.51 (4.35%) receiving and performance score of 43.49.

Average potential price target upside

of $397.26 (30.23%) on ASML (ASML HOLDING NV ADR).
of $28.31 (93.67%) on CGON (CG ONCOLOGY, COMMON STOCK).
of $21.42 (26.93%) on NUVL (NUVALENT).

INBX Inhibrx JNCE Jounce Therapeutics MGNX MacroGenics NKTX Nkarta ACET Adicet Bio ASML ASML Holding NV ADR BPMC Blueprint Medicines Corp CATX Perspective Therapeutics CGEM Cullinan Oncology LLC CGON CG Oncology, Common stock IDYA Ideaya Biosciences IOVA Iovance Biotherapeutics KURA Kura Oncology MRUS Merus BV NRIX Nurix Therapeutics NUVL Nuvalent SMMT Summit Therapeutics PLC SNDX Syndax Pharmaceuticals SONY Sony Group Corp

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Reni Benjamin (JMP)